Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017

LONZA GROUP

(LONN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Lonza : Previews its Newest Clean Label Innovation - Vcaps plus White Opal, a Titanium Dioxide-Free Capsule

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2019 | 07:19am EDT

Lonza today announces that its new Vcaps Plus White Opal capsule, which is designed to address the growing demand for opaque capsules that do not include titanium dioxide, is coming soon to the market.

By using an alternative opacifier, this new clean label capsule offers a natural semi-opaque look that masks unattractive food supplement ingredients. The new Vcaps Plus White Opal capsule will be presented next week at Vitafoods Europe 2019 in Geneva (CH), where Lonza is the Official Capsule Sponsor.

Demand for a Titanium Dioxide Alternative

Food-grade titanium dioxide, also known as E 171, is a common white pigment that has a long history of use in food supplement applications for its brightness and opacifying properties. However, recent scientific studies indicated potential risks associated with the presence of nanoparticles. Although the data is not conclusive and further research is needed, these findings question the justified use of nanoparticle titanium dioxide as a food additive. With strong ongoing public debate, the marketing of titanium dioxide-containing foodstuffs will be suspended in France beginning January 1, 2020.

As consumer awareness increases, supplement producers are seeking more natural alternatives that are free from titanium dioxide. Lonza's new Vcaps Plus White Opal capsule, the latest addition to its Capsugelrange of clean label plant-based capsules, is an ideal solution for supplement manufacturers.

Joachim Meier, Director, Head of Sales EMEA, Lonza Consumer Health & Nutrition, commented: 'With four out of five supplement users citing 'unquestionable safety' as a key decision-making factor when purchasing supplements, Lonza has developed the Vcaps Plus White Opal capsule as a high-quality, cutting-edge solution that meets evolving consumer preferences.

As a pioneer in vegetarian capsules with expertise in R&D, scale-up and the regulatory landscape, Lonza can help support supplement manufacturers in the development of innovative products with clean label benefits.'

Time for Color

Lonza will also be showcasing its expanding portfolio of clean label food colored capsules at Vitafoods, including the Vcaps Plus Blue Spirulina and Purple Carrot capsules and the soon-to-be launched Red Radish and Spicy Yellow. These next-generation capsules enable supplement brands to create vibrant products with colorful appeal, while also maintaining a natural appearance and delivering improved supply chain transparency.

Lonza is the Official Capsule Sponsor of Vitafoods Europe 2019. Lonza will be at booth G10, from 7-9 May, where attendees can talk to the experts or more information is available on www.capsugel.com

About Lonza

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum. Through our Lonza Pharma Biotech & Nutrition segment and our Lonza Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live. Founded in 1897 in the Swiss Alps, Lonza today is a wellrespected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion.

Contact:

Dirk Oehlers

Tel: +41 61 316 8540

Email: dirk.oehlers@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ('SGX-ST'). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LONZA GROUP
06/11LONZA : Engine Equipment Portfolio Launched for Small Molecule Formulation and D..
AQ
06/06LONZA : to Host New Webinar Titled 'Know Your Enemy Mycoplasma Contamination in ..
AQ
06/03Carve-out of Lonza Specialty Ingredients will help segment to become a global..
TE
05/21Global chemical firms urged to source responsibly after lethal China blast - ..
RE
05/18LONZA : Defense Logistics Agency Energy Aerospace Energy awarded $8m contract fo..
AQ
05/14LONZA : Chiasma and Lonza Announce Progression of Oral Octreotide Capsules Devel..
AQ
05/08LONZA : Showcases New SYNETH Product Range of Polyglycerol Esters for Perfect Ba..
AQ
05/07LONZA : Showcases New SYNETH™ Product Range of Polyglycerol Esters for Per..
PU
05/07LONZA : Highlights H2OBioEV™ Bioactive Functional for Skin Rejuvenation at..
PU
05/07LONZA : Previews its Newest Clean Label Innovation - Vcaps plus White Opal, a Ti..
AQ
More news
Financials (CHF)
Sales 2019 5 921 M
EBIT 2019 1 170 M
Net income 2019 808 M
Debt 2019 2 924 M
Yield 2019 0,90%
P/E ratio 2019 28,89
P/E ratio 2020 26,00
EV / Sales 2019 4,53x
EV / Sales 2020 4,18x
Capitalization 23 927 M
Chart LONZA GROUP
Duration : Period :
Lonza Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 335  CHF
Spread / Average Target 4,2%
EPS Revisions
Managers
NameTitle
Richard Ridinger Chief Executive Officer
Albert M. Baehny Chairman
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Margot A. Scheltema Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP29.21%24 012
IQVIA HOLDINGS INC21.63%26 223
CELLTRION, INC.--.--%20 953
INCYTE CORPORATION22.20%17 061
EXACT SCIENCES CORPORATION73.98%13 037
SEATTLE GENETICS, INC.20.90%10 947